Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer

Breast cancer is the most common cancer in a woman with a five-year survival of patients with metastatic disease is estimated at 23%. Ado-trastuzumab emtansine (T-DM1) is a HER2-antibody drug conjugate currently approved for the treatment of HER2-positive pre-treated metastatic breast cancer (BC). W...

Descripción completa

Detalles Bibliográficos
Autores principales: Manthri, Sukesh, Singal, Sakshi, Youssef, Bahaaeldin, Chakraborty, Kanishka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886650/
https://www.ncbi.nlm.nih.gov/pubmed/31824803
http://dx.doi.org/10.7759/cureus.6036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886650/
https://www.ncbi.nlm.nih.gov/pubmed/31824803
http://dx.doi.org/10.7759/cureus.6036

Ejemplares similares